Clinical trial

TherApeutics in Early ProState Cancer (TAPS02)

NCT05191680

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-04-24

PhasePHASE2

Study timeline

Study start (actual)2023-04-24Date precision: day

Registry last updated2025-06-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Apalutamide Oral Tablet [Erleada]DRUG · verified · RxNorm: apalutamide Oral Tablet [Erleada]

PlaceboDRUG

Sponsors & collaborators

Cambridge University Hospitals NHS Foundation Trustlead sponsor

University of Cambridgecollaborator

Janssen-Cilag Ltd.collaborator

Mapped research locations

LondonUnited Kingdom2 BristolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05191680 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.